跳到正文
原文
STAT 主站· Jason Mast·· 2026-10-08精选AI 评分67

Argenx的Vyvgart在干燥综合征III期试验中未优于安慰剂

STAT+: Argenx sees unusual setback with failure of late-stage study of drug for autoimmune disease

AI 导读

Argenx周四表示,其重磅药物Vyvgart在干燥综合征III期试验中未能优于安慰剂。这是该公司在自身免疫领域连续成功后罕见的挫败,当日早盘股价下跌13%。

推荐理由

该III期试验未显示Vyvgart优于安慰剂,是Argenx在自身免疫领域一系列成功后少见的挫败,或可助读者理解晚期临床试验的失败风险。

正文 · 原文

Vyvgart didn’t outperform placebo in a trial of patients with Sjögren’s disease

Stock exchange
Drew Angerer/Getty Images

By Jason Mast

Oct. 8, 2026

General Assignment Reporter

Jason is a general assignment reporter, with particular focus on genetic medicine and rare disease. Confidential tips can be sent on Signal at JasonMast.77.

Argenx said Thursday that its blockbuster drug Vyvgart didn’t outperform placebo in a Phase 3 trial of patients with Sjögren’s disease, a chronic autoimmune disorder.

It’s an unusual setback for Argenx, which has racked up a series of wins in autoimmune disorders en route to becoming one of the world’s largest biotechs by market cap. 

Argenx’s stock slipped 13% Thursday morning. 

STAT+ Exclusive Story

Already have an account? Log in

STAT+

STAT+

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

View All Plans

To read the rest of this story subscribe to STAT+.

Subscribe

  1. General Assignment Reporter

    Jason is a general assignment reporter, with particular focus on genetic medicine and rare disease. Confidential tips can be sent on Signal at JasonMast.77.

来源:STAT 主站 · statnews.com